Search

Your search keyword '"Perl, Alexander"' showing total 441 results

Search Constraints

Start Over You searched for: Author "Perl, Alexander" Remove constraint Author: "Perl, Alexander" Language english Remove constraint Language: english
441 results on '"Perl, Alexander"'

Search Results

1. Cytokine-mediated CAR T therapy resistance in AML

2. Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia

3. Evolving racial/ethnic disparities in AML survival in the novel therapy era

4. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML

5. Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia

8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

9. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

10. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

11. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).

13. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients

19. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

22. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial

23. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

24. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

27. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

31. AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

32. AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

34. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

38. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

40. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.

41. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers.

45. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay

48. Testing the Perceived Ease of Use in Social Media : Acceptance Testing for People with Intellectual and Cognitive Disabilities

50. Crenolanib is a selective type I pan-FLT3 inhibitor

Catalog

Books, media, physical & digital resources